BioCardia, Inc. (BCDA): Price and Financial Metrics
BCDA Price/Volume Stats
| Current price | $2.17 | 52-week high | $5.04 |
| Prev. close | $2.13 | 52-week low | $1.63 |
| Day low | $2.10 | Volume | 13,125 |
| Day high | $2.19 | Avg. volume | 69,471 |
| 50-day MA | $2.27 | Dividend yield | N/A |
| 200-day MA | $2.40 | Market Cap | 11.24M |
BCDA Stock Price Chart Interactive Chart >
BioCardia, Inc. (BCDA) Company Bio
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
BCDA Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BCDA Price Returns
| 1-mo | -18.11% |
| 3-mo | -17.18% |
| 6-mo | 2.36% |
| 1-year | -50.29% |
| 3-year | -91.07% |
| 5-year | N/A |
| YTD | -0.46% |
| 2024 | -78.12% |
| 2023 | -68.22% |
| 2022 | 7.73% |
| 2021 | -43.93% |
| 2020 | -5.98% |